---
title: Lactose + Meningococcal  Polysaccharide Vaccine
description: >-
  - **Medical Conditions:** This vaccine is prescribed for active immunization
  against invasive meningococcal disease caused by *Neisseria meningitidis*
  serogroups A, C, Y, and W-135. It does *not* protect against serogroup B. -
  **Pharmacological Classification:** Vaccine - **Mechanism of Action:**...
is_banned: false
lastModified: '2025-09-22T17:22:09.452Z'
faqs:
  - q: >-
      What is the recommended dosage for Lactose + Meningococcal  Polysaccharide
      Vaccine?**


      **A:** A single 0.5 mL dose is given subcutaneously.
    a: 'A:** A single 0.5 mL dose is given subcutaneously.'
  - q: >-
      Who should receive this vaccine?**


      **A:** Individuals at risk of exposure to *N. meningitidis* serogroups A,
      C, Y, and W-135, such as travelers to endemic areas, military recruits,
      individuals with asplenia or complement deficiencies, and those exposed
      during outbreaks.
    a: >-
      A:** Individuals at risk of exposure to *N. meningitidis* serogroups A, C,
      Y, and W-135, such as travelers to endemic areas, military recruits,
      individuals with asplenia or complement deficiencies, and those exposed
      during outbreaks.
  - q: >-
      Does this vaccine protect against all types of meningococcal disease?**


      **A:** No, it does *not* protect against serogroup B meningococcal
      disease.
    a: 'A:** No, it does *not* protect against serogroup B meningococcal disease.'
  - q: >-
      Can this vaccine be given to pregnant or breastfeeding women?**


      **A:**  It should only be given during pregnancy if clearly needed, and
      caution is advised during breastfeeding.
    a: >-
      A:**  It should only be given during pregnancy if clearly needed, and
      caution is advised during breastfeeding.
  - q: >-
      What are the most common side effects?**


      **A:** Injection site reactions (pain, redness, swelling), headache,
      fatigue, and fever.
    a: >-
      A:** Injection site reactions (pain, redness, swelling), headache,
      fatigue, and fever.
  - q: >-
      How long does protection from the vaccine last?**


      **A:** Antibody levels decline over time. Booster doses may be needed
      depending on individual risk factors.
    a: >-
      A:** Antibody levels decline over time. Booster doses may be needed
      depending on individual risk factors.
  - q: >-
      Can this vaccine be administered with other vaccines?**


      **A:** Yes, it can be given concurrently with other vaccines, but at a
      different injection site.
    a: >-
      A:** Yes, it can be given concurrently with other vaccines, but at a
      different injection site.
  - q: >-
      What should be done if a patient experiences a severe allergic reaction?**


      **A:** Immediate medical attention and administration of epinephrine if
      necessary.
    a: >-
      A:** Immediate medical attention and administration of epinephrine if
      necessary.
  - q: >-
      Is there a specific treatment for meningococcal disease?**


      **A:** Yes, meningococcal disease is treatable with antibiotics, but
      prevention through vaccination is the best approach.
    a: >-
      A:** Yes, meningococcal disease is treatable with antibiotics, but
      prevention through vaccination is the best approach.
---
## **Usage**

- **Medical Conditions:** This vaccine is prescribed for active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. It does *not* protect against serogroup B.
- **Pharmacological Classification:** Vaccine
- **Mechanism of Action:**  The vaccine stimulates the immune system to produce antibodies against the specific polysaccharides of the four meningococcal serogroups (A, C, Y, and W-135).  These antibodies then provide protection against invasive disease caused by these bacteria. Lactose is added as a stabilizer.

## **Alternate Names**

- **Generic Name:** Meningococcal Polysaccharide Vaccine (Groups A, C, Y, W-135 combined)
- **Brand Name:** Menomune®

## **How It Works**

- **Pharmacodynamics:** The vaccine induces an immune response by presenting the polysaccharide antigens to the body's immune system. B-lymphocytes recognize these antigens and produce specific antibodies, primarily IgG.
- **Pharmacokinetics:** The polysaccharide antigens are poorly absorbed and remain localized at the injection site where they interact with immune cells.  The generated antibodies are distributed systemically. The elimination of the polysaccharides and their conjugates are not fully elucidated but presumed to occur through natural degradation.
- **Mode of Action:** The vaccine prompts a T cell-independent B cell response, leading to the production of antibodies directed against the capsular polysaccharides of *N. meningitidis*.
- **Elimination Pathways:** The elimination of the polysaccharides themselves is not specifically described.

## **Dosage**

### **Standard Dosage**

#### **Adults:** A single 0.5 mL dose subcutaneously.

#### **Children (2 years and older):** A single 0.5 mL dose subcutaneously. Children younger than two years of age should only be vaccinated during an outbreak of serotype A, as recommended by relevant health authorities.

#### **Special Cases:**

- **Elderly Patients:** Standard adult dose.
- **Patients with Renal Impairment:** Standard adult dose.
- **Patients with Hepatic Dysfunction:** Standard adult dose.
- **Patients with Comorbid Conditions:**  Standard adult dose, though caution should be exercised in patients with compromised immune systems.

### **Clinical Use Cases**

The vaccine is for *pre-exposure prophylaxis*, not for treatment of existing infection. It is not used in the settings of intubation, surgical procedures, mechanical ventilation, ICU use, or during emergency situations such as cardiac arrest.

### **Dosage Adjustments**

No dose adjustments are typically necessary for specific medical settings or patient-specific factors.

## **Side Effects**

### **Common Side Effects:**
- Localized injection site reactions (pain, redness, swelling, tenderness, induration)
- Headache
- Fatigue/Drowsiness
- Fever
- Myalgia

### **Rare but Serious Side Effects:**
- Allergic reactions (including anaphylaxis)
- Neurological reactions (e.g., Guillain-Barré syndrome - rare)

### **Long-Term Effects:** No long-term adverse effects have been specifically reported.

### **Adverse Drug Reactions (ADR):**  Anaphylaxis, though rare, warrants immediate medical intervention.


## **Contraindications**

- Hypersensitivity to any component of the vaccine, including lactose.
- History of severe allergic reaction to a previous dose of the vaccine.

## **Drug Interactions**

- **Immunosuppressants/Corticosteroids:** May reduce the immune response to the vaccine.
- **Other Vaccines:** Can be administered concomitantly but at different injection sites.

## **Pregnancy and Breastfeeding**

- **Pregnancy:** Use only if clearly needed, as data on use during pregnancy are limited.
- **Breastfeeding:** Caution should be exercised.  It is not known whether the vaccine is excreted in human milk.


## **Drug Profile Summary**

- **Mechanism of Action:** Stimulates antibody production against meningococcal polysaccharides.
- **Side Effects:** Injection site reactions, headache, fatigue, fever, myalgia. Rare: allergic reaction.
- **Contraindications:** Hypersensitivity to any component of the vaccine.
- **Drug Interactions:** Immunosuppressants may reduce efficacy.
- **Pregnancy & Breastfeeding:**  Limited data in pregnancy. Caution advised during breastfeeding.
- **Dosage:** Single 0.5 mL dose subcutaneously.
- **Monitoring Parameters:** No specific monitoring is usually required beyond observation for immediate allergic reactions post-vaccination.


## **Popular Combinations**

It's not typically combined with other drugs, but can be given with other vaccines.

## **Precautions**

- Screen for contraindications prior to administration.
- Have appropriate medical treatment available in case of an allergic reaction.

## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Lactose + Meningococcal  Polysaccharide Vaccine?**

**A:** A single 0.5 mL dose is given subcutaneously.

### **Q2: Who should receive this vaccine?**

**A:** Individuals at risk of exposure to *N. meningitidis* serogroups A, C, Y, and W-135, such as travelers to endemic areas, military recruits, individuals with asplenia or complement deficiencies, and those exposed during outbreaks.

### **Q3: Does this vaccine protect against all types of meningococcal disease?**

**A:** No, it does *not* protect against serogroup B meningococcal disease.

### **Q4:  Can this vaccine be given to pregnant or breastfeeding women?**

**A:**  It should only be given during pregnancy if clearly needed, and caution is advised during breastfeeding.

### **Q5: What are the most common side effects?**

**A:** Injection site reactions (pain, redness, swelling), headache, fatigue, and fever.

### **Q6:  How long does protection from the vaccine last?**

**A:** Antibody levels decline over time. Booster doses may be needed depending on individual risk factors.

### **Q7: Can this vaccine be administered with other vaccines?**

**A:** Yes, it can be given concurrently with other vaccines, but at a different injection site.

### **Q8: What should be done if a patient experiences a severe allergic reaction?**

**A:** Immediate medical attention and administration of epinephrine if necessary.

### **Q9: Is there a specific treatment for meningococcal disease?**

**A:** Yes, meningococcal disease is treatable with antibiotics, but prevention through vaccination is the best approach.



